ASSESSMENT OF EFFICACY OF TYROSINE KINASE INHIBITORS IN TREATMENT OF CHRONIC MYELOID LEUKEMIA

被引:0
|
作者
Yadrikhinskaya, V. N. [1 ,2 ]
Mulina, I. I. [3 ,4 ]
Sannikova, A. N. [5 ]
Palshina, A. M. [1 ,2 ]
Sleptsova, S. S. [1 ,6 ,7 ]
Aleksandrova, T. N. [8 ]
机构
[1] MK Ammosov North Eastern Fed Univ, Med Sci, Inst Med, Ojunsky St 27, Yakutsk 677000, Russia
[2] Dept Hosp Therapy Occupat Dis & Clin Pharmacol, Ojunsky St 27, Yakutsk 677000, Russia
[3] Minist Healthcare Republ Sakha Yakutia, Sergelyakhskoe Shosse 4, Yakutsk 677019, Russia
[4] Dept Hematol Republican Hosp 1 Natl Ctr Med, Sergelyakhskoe Shosse 4, Yakutsk 677019, Russia
[5] Natl Ctr Med, Dept Hematol, Sergelyakhskoe Shosse 4, Yakutsk 677019, Russia
[6] MK Ammosov North Eastern Fed Univ, Minist Healthcare Republ Sakha Yakutia, Inst Med, Ojunsky St 27, Yakutsk 677000, Russia
[7] MK Ammosov North Eastern Fed Univ, Sci, Ojunsky St 27, Yakutsk 677000, Russia
[8] MK Ammosov North Eastern Fed Univ, Inst Med, Dept Internal Dis & Gen Med, Ojunsky St 27, Yakutsk 677000, Russia
来源
YAKUT MEDICAL JOURNAL | 2016年 / 04期
关键词
chronic myeloid leukemia; tyrosine kinase inhibitors; imatinib;
D O I
暂无
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
This research demonstrated treatment results of 45 patients with chronic myeloid leukemia who were monitored from 2006 to 2015 year. The article is aimed to evaluate a frequency of achievement of hematologic, cytogenetic, molecular responses in patients administered with tyrosine kinase inhibitors, prevalence of resistance to imatinib and its toxicity. It is shown that the treatment of choice for CML is tyrosine kinase inhibitor - imatinib. The use of tyrosine kinase inhibitors allows to reach deep cytogenetic and molecular remission in patients with chronic myeloid leukemia which leads to increased survival. Authors have noted a high prevalence of primary and secondary resistance to first generation tyrosine kinase inhibitor - imatinib. Investigation of results demonstrated that regular hematological, cytogenetic and molecular monitoring is required for effective disease control.
引用
收藏
页码:30 / 33
页数:4
相关论文
共 50 条
  • [31] Current Management of Chronic Myeloid Leukemia with Tyrosine Kinase Inhibitors
    Haznedaroglu, Ibrahim C.
    TURKISH JOURNAL OF HEMATOLOGY, 2013, 30 (03) : 247 - 255
  • [32] Chronic myeloid leukemia, tyrosine kinase inhibitors and cardiovascular system
    Malkan, U. Y.
    Haznedaroglu, I. C.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2023, 27 (12) : 5493 - 5506
  • [33] Treating Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors
    Gale, Robert Peter
    Goldman, John M.
    ACTA HAEMATOLOGICA, 2013, 130 (03) : 192 - 195
  • [34] Discontinuation of tyrosine kinase inhibitors in pediatric chronic myeloid leukemia
    Shima, Haruko
    Kada, Akiko
    Tanizawa, Akihiko
    Sato, Iori
    Tono, Chikako
    Ito, Masaki
    Yuza, Yuki
    Watanabe, Akihiro
    Kamibeppu, Kiyoko
    Uryu, Hideko
    Koh, Katsuyoshi
    Imai, Chihaya
    Yoshida, Nao
    Koga, Yuhki
    Fujita, Naoto
    Saito, Akiko M.
    Adachi, Souichi
    Ishii, Eiichi
    Shimada, Hiroyuki
    PEDIATRIC BLOOD & CANCER, 2022, 69 (08)
  • [35] The Association of Tyrosine Kinase Inhibitors with Obesity in Chronic Myeloid Leukemia
    Rajan, Raeesha
    Karia, Esha
    Samaan, M. Constantine
    Balakumaran, Janatani
    Golemiec, Breanne
    Spatafora, Laura
    Banfield, Laura
    Athale, Uma
    Thabane, Lehana
    Fleming, Adam
    Samaan, Constantine
    OBESITY, 2021, 29 : 172 - 172
  • [36] Vitamin D and tyrosine kinase inhibitors in chronic myeloid leukemia
    Campiotti, Leonardo
    Bolzacchini, Elena
    Sutter, Matteo Basilio
    Maresca, Andrea Maria
    Grandi, Anna Maria
    Guasti, Luigina
    INTERNAL AND EMERGENCY MEDICINE, 2018, 13 (08) : 1337 - 1339
  • [37] Tyrosine Kinase Inhibitors and Beyond for Chronic Myeloid Leukemia in Children
    Phillips, Lia N.
    Hijiya, Nobuko
    PEDIATRIC DRUGS, 2021, 23 (03) : 241 - 251
  • [38] The Applicability of Tyrosine Kinase Inhibitors in Pediatric Chronic Myeloid Leukemia
    Ata, Fateen
    Ghasoub, Rola
    Benkhadra, Maria
    Fernyhough, Liam
    Aldapt, Mahmood
    Omar, Nabil E.
    Nashwan, Abdulqadir
    Mushtaq, Kamran
    Yassin, Mohamed A.
    BLOOD, 2023, 142
  • [39] A safety review of tyrosine kinase inhibitors for chronic myeloid leukemia
    Ozmen, Deniz
    Alpaydin, Duygu Demet
    Saldogan, Muhammed Ali
    Eskazan, Ahmet Emre
    EXPERT OPINION ON DRUG SAFETY, 2024, 23 (04) : 411 - 423
  • [40] Tyrosine Kinase Inhibitors and Beyond for Chronic Myeloid Leukemia in Children
    Lia N. Phillips
    Nobuko Hijiya
    Pediatric Drugs, 2021, 23 : 241 - 251